| Ytd | -65.65% | |
| 1y | -40.05% |
| Open | 3.83 | Prev Close | 3.85 | Low | 3.80 | High | 3.89 | Mkt Cap | 296.41M |
| Vol | 695.36K | Avg Vol | 2.89M | EPS | -1.21 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 3.05 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 3.73 | 200-d Avg | 7.45 | 1yr Est | 5.29 |
FULC News
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 28,
New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, T
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick and F
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Fulcrum Therapeutics (NASDAQ: FULC) has entered into an all-stock merger agreement with privately he
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17,
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Pri
MILWAUKEE, Aug. 17, 2026 /PRNewswire/ -- Ademi LLP is investigating Fulcrum (Nasdaq: FULC) for possi
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backe
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Fulcrum Therapeutics NASDAQ: FULC has entered into an all-stock merger agreement with privately held
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-sto
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-gene
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restru
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade T
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweig
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outpe
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC,
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concern
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the anal
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), re